Fulgent Therapeutics, based in Temple City, California, specializes in providing genetic testing services that deliver clinically actionable diagnostic information to physicians. The company utilizes a robust technology platform that combines data comparison algorithms, adaptive learning software, and integrated laboratory processes to enhance its genetic diagnostics capabilities. Fulgent Therapeutics offers a range of testing services, including traditional single-gene tests and advanced panel-based tests developed through Next Generation Sequencing (NGS) technology. The company primarily serves hospitals and medical institutions, marketing its tests through both an internal salesforce and independent representatives in the United States and internationally. Additionally, Fulgent Therapeutics has partnered with PWNHealth to facilitate at-home Covid-19 testing, reflecting its commitment to expanding accessible healthcare solutions. Founded in 2011, the company has evolved from its original name, Fulgent Diagnostics, to its current branding in 2016.
Spatial Genomics is an innovative leaders in the field of spatial analysis, we are dedicated to empowering discovery.We believe that Spatial Genomics will become a standard research tool used routinely by labs worldwide.
CSI Laboratories, founded in 1997, specializes in personalized diagnostic testing primarily for the pathology community. Initially established as a flow cytometry laboratory, it has since expanded its services to include cytogenetics and molecular genetics, incorporating fluorescence in-situ hybridization and immunohistochemistry. In 2005, the company broadened its offerings by launching cytogenetics and molecular genetics laboratories and further enhanced its capabilities with an extensive immunohistochemistry laboratory in 2007. CSI Laboratories provides a range of diagnostic services, including next-generation sequencing and consultations for hematopathology and surgical pathology clients. Throughout its operations, the company has maintained a strong commitment to client service and patient care, positioning itself as a vital resource for pathologists and clinicians across the nation.
FF Gene Biotech
Acquisition in 2021
FF Gene Biotech was founded to bring Fulgent Genetics’ Next Generation Sequencing (NGS) capabilities to the Chinese genetic testing market.
Laboratory for Advanced Medicine Inc. is an artificial intelligence-driven healthcare company specializing in methylation-based cancer detection tests. Founded in 2014, the company emerged from research at the Institute of Genomic Medicine at the University of California, San Diego, which identified methylation as an effective method for cancer detection. Laboratory for Advanced Medicine operates CLIA and CAP certified laboratories, as well as cGMP facilities, to advance the commercialization of these technologies. Its focus includes developing diagnostic tests for various cancers, such as colon and breast cancer. Headquartered in Irvine, California, the company also has offices in Indiana and collaborates with leading scientists, physicians, and research institutions in both the United States and China.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.